TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03408808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: Aspiration of ganglion and injection with platelet rich plasma.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aspiration alone
Description: Aspiration of the ganglion
Study: NCT02920294

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic 1
Description: Fresh fermented dairy drink containing yoghurt ferments

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic 2
Description: Fresh fermented dairy drink containing probiotic strain

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acidified dairy drink without ferments
Study: NCT02451007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurbinectedin (PM01183)
Study: NCT03570385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI in diffusion tensor (DTI : Diffusion Tensor Imaging)
Study: NCT02327143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2835219
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ¹³C₈-LY2835219
Description: Administered IV
Study: NCT03224377

Intervention type: DIAGNOSTIC_TEST
Intervention: anti mutated citrullinated vimentin antibodies
Description: Blood sampling using ELisa technique

Intervention type: DIAGNOSTIC_TEST
Intervention: anti mutated citrullinated vimentin antibodies
Description: Blood sampling using ELisa technique
Study: NCT00742690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: terlipressin given by intravenous boluses and albumin
Description: Patients who will be randomly assigned to arm 1 will received terlipressin given by intravenous boluses at the initial dose of terlipressin was 0.5 mg/4 hr. In case of non response, the dose of terlipressin was progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given intravenously at the dose of 1 g/kg of body weight on the first day followed by 20-40 g/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terlipressin given by continuous intravenous infusion and albumin
Description: Patients who will be randomly assigned to arm 1 will received terlipressin given as intravenous boluses at the initial dose of 0.5 mg/4 hr. In case of non response, the dose of terlipressin will be progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given at the dose of 1 g/kg of body weight at the first day followed by 20-40 g/day.
Study: NCT04105257

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: All patients
Description: Comparison of the results of the CTP with MRI
Study: NCT01872182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-L1023
Description: daily twice for 12 weeks
Study: NCT02565927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine-125 seeds
Description: process intraluminal brachytherapy
Study: NCT01872182

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: daily twice for 12 weeks
Study: NCT00930800

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Using a video game so-called Dance Dance Revolution (DDR)
Study: NCT02674256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRH
Description: 100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together, then the solution will be injected intravenously over the course of 1 minute

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL of NaCl 0.9% will be injected intravenously over the course of one minute
Study: NCT04082039

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: convetional PCA method unsing only 1-channel
Description: Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: utilizing 2-channel
Description: Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
Study: NCT00825851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal nicotine patch
Description: 15mg/16h + 10mg/16h to be used 24h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Study: NCT04869410

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modification Broselow Tape
Description: Intubation using modified Broselow Tape prediction for predicting ETT size

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modification Broselow Tape
Description: Intubation using modified Broselow Tape prediction for predicting ETT size

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cole Formula
Description: Intubation using Cole Formula prediction for predicting ETT size

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cole Formula
Description: Intubation using Cole Formula prediction for predicting ETT size
Study: NCT02729012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline solution (NACL 3%+NAHCO3)
Description: Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution (NACL 0,9%)
Description: Treatment with nebulized Saline Solution (NACL 0,9%)
Study: NCT04147234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1387446
Description: intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1387446
Description: intratumoral injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: intravenous infusion
Study: NCT02682251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHR Messaging
Description: PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
Study: NCT04348058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone recruitment to screening colonoscopy
Description: Utilisation of dedicated call center for recruitment to screening program instead of traditional, paper invitation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined methods recruitment to screening colonoscopy
Description: Utilisation of dedicated call center for recruitment to screening program in participants, who did not respond to traditional, paper invitation
Study: NCT00638391

Intervention type: DRUG
Intervention: Anastrozole
Study: NCT01266200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mantis
Description: percutaneous minimal-invasive technique at the thoracal-lumbal junction with for cuts of about 3 cms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: XIA
Description: Treatment of the fracture with Xia and conventional operation technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: XIA
Description: Treatment of the fracture with Xia and conventional operation technique
Study: NCT01507103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide (CPA)
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m\^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m\^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m\^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
Study: NCT01485198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Autologous Stem Cells Infusion
Description: Extraction and knee infusion of Bone Marrow Autologous Stem Cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen (750mg orally TID) administration
Study: NCT02773823

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Diet instruction for 3-4 times/semester,exercise 60min/day for 5d/week for 8 months.
Study: NCT00825851

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking cessation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous smoking
Description: subjects smoke 20 cigarettes per day
Study: NCT04496934

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise of choice with a training contact: 3 hrs/week, total of 12 weeks.
Study: NCT02195284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS/ACCUHALER
Description: Placebo inhaler with one blister strip containing lactose monohydrate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDI
Description: Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TURBUHALER
Description: Placebo inhaler containing lactose monohydrate.
Study: NCT02970058

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich Plasma
Description: The active group will receive Platelet-rich Plasma following spinal injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will receive saline as a placebo
Study: NCT02943499

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: App/Training
Description: This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
Study: NCT03260439

Intervention type: DRUG
Group type: OTHER
Intervention: Tramadol
Description: Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
Study: NCT06693219

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasonography to confirm the correct placement of a nasogastric tube in the stomach
Description: The sonographic examination consisted of three parts: neck scan, epigastric scan, and injection test using a mixture of 25 mL NaCl 0.9% and 25 mL room air through the nasogastric tube to detect dynamic fogging
Study: NCT06693349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the effect of platelet-rich fibrin in treatment of contaminated and uncontaminated immature permanent teeth
Description: this procedure was anticipated to give superior effects than other procedure used in this study
Study: NCT04929821

Intervention type: DEVICE
Group type: OTHER
Intervention: Biliary Duct Stenting
Description: UNITY-B Balloon-expandable Biodegradable Biliary Stent deployment in obstructed biliary ducts.
Study: NCT00287053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex sodium
Description: Divalproex sodium vs. placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: divalproex sodium
Description: Divalproex sodium vs. placebo
Study: NCT01013818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGS1029
Description: HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
Study: NCT02373839

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of PlGF
Description: If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks
Study: NCT04929730

Intervention type: OTHER
Group type: OTHER
Intervention: Nephrology care bundle
Description: Nephrology care bundle
Study: NCT02625311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery method using CR TKP
Description: Operation through minimal invasive surgery or standard open surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery method using CR TKP
Description: Operation through minimal invasive surgery or standard open surgery
Study: NCT03727139

Intervention type: DRUG
Intervention: Rasagiline
Description: Rasagiline Tablets
Study: NCT02242734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg HC-ER
Description: 1-72 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg HC-ER
Description: 1-72 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg HC-ER
Description: 1-72 hours
Study: NCT03150901

Intervention type: DIAGNOSTIC_TEST
Intervention: no drug
Description: laboratory tests
Study: NCT03937206

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NutriterraTM
Description: Nutriterra 1000mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NutriterraTM
Description: Nutriterra 1000mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NutriterraTM
Description: Nutriterra 1000mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Corn Oil 1000mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Corn Oil 1000mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn Oil 1000mg
Study: NCT04123587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: discontinuation of Sulfonylureas
Description: 1. Discontinuation of sulfonylurea, alternative drug administration.~2. If there is a significant increase in blood glucose, it is considered as a sulfonylurea-dependent patient. Discontinue the alternative drug and resume the sulfonylurea, and monitor for 12 weeks or until stabilization of blood glucose at short intervals.~3. if blood glucose levels are within optimal range after replacement of sulfonylureas with other agents, the patient is regard as non-SU-dependent
Study: NCT03141580

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS)
Description: Examination of the extracranial portion of the internal and common carotid artery with pre-existing stent with NIRS-IVUS.
Study: NCT05204537

Intervention type: PROCEDURE
Intervention: Lung parenchyma resection
Description: Lung parenchyma removal

Intervention type: PROCEDURE
Intervention: Empyemectomy
Description: Intrapleural cavity effusion removal, parietal pleura removal.
Study: NCT03735706

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation dose reduction
Description: The radiation dose is is different between groups

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation dose reduction
Description: The radiation dose is is different between groups

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation dose reduction
Description: The radiation dose is is different between groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast media volume reduction
Description: Contrast media volume is different between groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast media volume reduction
Description: Contrast media volume is different between groups

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Unenhanced slice
Description: One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Unenhanced slice
Description: One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Unenhanced slice
Description: One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Unenhanced slice
Description: One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Weight
Description: A weighing scale is used to measure a patients body weight right before the scan.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Weight
Description: A weighing scale is used to measure a patients body weight right before the scan.
Study: NCT02943499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App/Training
Description: It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Study: NCT05601063

Intervention type: BEHAVIORAL
Intervention: Winterlight Speech Assessment
Description: Digital assessment of speech and language abilities

Intervention type: BEHAVIORAL
Intervention: Winterlight Speech Assessment
Description: Digital assessment of speech and language abilities
Study: NCT04029662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Valsalva Maneuver
Description: Performing Valsalva maneuver will reduce the pain intensity during spinal needle insertion.
Study: NCT02105012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD MDI 320 µg
Description: Budesonide Inhalation Aerosol administered as 2 inhalations BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD MDI 160 µg
Description: Budesonide Inhalation Aerosol administered as 2 inhalations BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD MDI 80 µg
Description: Budesonide Inhalation Aerosol administered as 2 inhalations BID
Study: NCT03735706

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Weight
Description: A weighing scale is used to measure a patients body weight right before the scan.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Weight
Description: A weighing scale is used to measure a patients body weight right before the scan.